As reported on PharmaBiz, Regenxbio has announced encouraging topline findings from the pivotal Phase III portion of its ongoing AFFINITY DUCHENNE clinical program evaluating RGX-202, an investigational gene therapy for Duchenne muscular dystrophy (DMD). The results highlight both strong biomarker expression and early indications of functional benefit, reinforcing the therapy’s potential as a meaningful advance in the treatment of this rare and progressive neuromuscular disorder.
Strong Efficacy Signals Observed
The study achieved its primary endpoint with high statistical significance, with the vast majority of treated participants demonstrating clinically relevant levels of microdystrophin expression at 12 weeks. Specifically, more than nine out of ten patients reached at least 10% expression, while average levels exceeded 70% across the cohort. Older participants—who typically experience more advanced disease progression—also showed measurable expression, though at lower average levels.
Importantly, investigators reported a statistically significant association between biomarker expression and functional outcomes. This relationship suggests that increases in microdystrophin—the protein engineered to compensate for the defective dystrophin in DMD—may translate into tangible clinical improvements, a key consideration in gene therapy development.
Signs of Functional Improvement
Interim functional data from a subset of ambulatory boys aged approximately 5 to 12 years indicate improvements in mobility and physical performance one year after treatment. Evaluations using the North Star Ambulatory Assessment (NSAA) and timed function tests (such as standing, walking, and climbing tasks) demonstrated better outcomes compared with externally derived control data.
These improvements were observed using a propensity score–weighted comparison model, the prespecified analytical approach for the study. The correlation between early microdystrophin levels and subsequent functional gains further strengthens the case for RGX-202’s therapeutic effect.
Safety Profile Remains Manageable
The gene therapy was generally well tolerated across study participants. Most treatment-related adverse events—including nausea, fatigue, and vomiting—were mild to moderate and resolved without lasting effects. Two serious adverse events were reported, involving myocarditis and liver injury; both cases resolved within weeks and did not result in long-term complications.
Liver-related biomarkers remained within normal ranges up to one year post-treatment in the subset of patients evaluated, suggesting no sustained liver toxicity. Investigators attribute the safety profile, in part, to a combination of proactive immune suppression strategies and improvements in vector design and manufacturing purity.
Trial Design and Ongoing Development
The pivotal trial evaluated a single-dose intravenous administration of RGX-202 in ambulatory boys aged one year and older. Additional participants are currently being enrolled in a confirmatory cohort, with dosing expected to be completed across both cohorts in the near term.
Regulatory discussions are ongoing, with the U.S. Food and Drug Administration indicating openness to considering microdystrophin expression as a surrogate endpoint—provided its relationship to clinical outcomes is sufficiently demonstrated, as appears to be the case in these interim data.
Regenxbio is planning further engagement with regulators and is preparing for a potential accelerated approval pathway. A global study is also being developed to support regulatory submissions outside the United States.
A Differentiated Approach to Gene Therapy
RGX-202 is designed to deliver a functional microdystrophin construct that closely resembles the natural protein. Unlike other approaches, it includes a specific domain believed to enhance muscle stability and function. The therapy also incorporates a high-purity viral vector and an optimized manufacturing process aimed at improving durability and safety.
Addressing a Critical Unmet Need
Duchenne muscular dystrophy is a severe, inherited disorder characterized by progressive muscle degeneration caused by mutations in the gene responsible for producing dystrophin. The disease primarily affects boys and leads to loss of mobility, respiratory complications, cardiac involvement, and reduced life expectancy.
Despite advances in supportive care and emerging therapies, there remains a significant need for treatments that can fundamentally alter disease progression. The latest findings from the AFFINITY DUCHENNE program suggest that RGX-202 may represent a promising step toward that goal.
Looking Ahead
Based on the positive data, Regenxbio is advancing plans for regulatory submission and a potential commercial launch within the next few years. While longer-term outcomes and confirmatory data are still needed, the current results provide renewed optimism for patients and families affected by Duchenne muscular dystrophy, as well as for the broader field of gene therapy.
